TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36271912

Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral small molecule Janus kinase inhibitor)
Number of subjects: 0
Study: 36272877

Group type: EXPERIMENTAL
Intervention: dTaP-IPV booster vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pertussis-containing vaccine
Number of subjects: 0
Study: 36272997

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment (HT) administered to 670 newborns (84.4%)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Risk factors associated with death
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Neurological status
Number of subjects: 794
Study: 36273191

Group type: EXPERIMENTAL
Intervention: Mr. MAPP (Mixed reality system for Managing Phantom Pain)
Number of subjects: 7
Study: 36273204

Group type: EXPERIMENTAL
Intervention: Viewing emotionally expressive faces
Number of subjects: 0
Study: 36273221

Group type: EXPERIMENTAL
Intervention: Tailored motivational interviewing
Number of subjects: 128

Group type: COMPARATOR
Intervention: Individually focused HIV prevention intervention
Number of subjects: 128
Study: 36273324

Group type: EXPERIMENTAL
Intervention: FLASH radiotherapy (≥40 Gy/sec)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard of care (conventional-dose-rate photon radiotherapy at approximately 0.03 Gy/sec)
Number of subjects: 10
Study: 36273417

Group type: EXPERIMENTAL
Intervention: FFR-guided deferred-PCI with abnormal resting Pd/Pa
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: FFR-guided deferred-PCI with abnormal CFR
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Age correlation with FFR
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Age correlation with resting Pd/Pa
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Age correlation with CFR
Number of subjects: 1134
Study: 36273822

Group type: EXPERIMENTAL
Intervention: M3258, an orally bioavailable, potent, selective, reversible inhibitor of LMP7
Number of subjects: 0
Study: 36273986

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza A/H7N9 vaccine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unadjuvanted influenza A/H7N9 vaccine
Number of subjects: 37
Study: 36274108

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Heparin during the procedure
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Admission NIHSS ≥ 26
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Time from onset to puncture (OTP) ≥ 395 min
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Procedure duration ≥ 102 min
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Admission NIHSS > 36 vs. ≤ 11
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: OTP > 441 min vs. ≤ 210 min
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Procedure duration > 145 min vs. ≤ 59 min
Number of subjects: 347
Study: 36274113

Group type: EXPERIMENTAL
Intervention: Stable compensated cirrhosis (CC) patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 28
Study: 36274161

Group type: EXPERIMENTAL
Intervention: Triptolide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guanosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 0
Study: 36274263

Group type: EXPERIMENTAL
Intervention: Prophylactic donor lymphocyte infusion (DLI) administered at 30 days after transplantation for HLA-matched related HSCT or at 45-60 days for haploidentical/unrelated HSCT.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard of care therapy (control group).
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Total therapy (including allo-HSCT and prophylactic DLI).
Number of subjects: 105
Study: 36274573

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered every 2 weeks until disease progression, unacceptable toxicity, or 12 months of treatment.
Number of subjects: 24
Study: 36275049

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 75
Study: 36275655

Group type: EXPERIMENTAL
Intervention: HIV Env Mosaic immunogens combined with a liposomal toll-like receptor-4 adjuvant; monophosphoryl lipid A
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HIV Env Mosaic immunogens combined with adjuvant
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HIV immunogens
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Repeated experimental HIV immunization
Number of subjects: 11
Study: 36275715

Group type: EXPERIMENTAL
Intervention: Low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy combined with Bruton's tyrosine kinase inhibitor and PD-1 antibody.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy.
Number of subjects: 1
Study: 36275912

Group type: EXPERIMENTAL
Intervention: BMS-986012 + nivolumab
Number of subjects: 106

Group type: COMPARATOR
Intervention: BMS-986012 monotherapy
Number of subjects: 106
Study: 36275941

Group type: EXPERIMENTAL
Intervention: SCTaware virtual program
Number of subjects: 7

Group type: COMPARATOR
Intervention: In-person SCT education
Number of subjects: 7
Study: 36276500

Group type: EXPERIMENTAL
Intervention: SIX1 upregulation in HCV-positive female patients with HCC
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SIX1 upregulation
Number of subjects: 78
Study: 36276877

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination intent
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination acceptability
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Change in vaccine intent
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Vaccine acceptability related to mental health
Number of subjects: 117
Study: 36277312

Group type: EXPERIMENTAL
Intervention: Optimised SPC surveillance
Number of subjects: 204233

Group type: COMPARATOR
Intervention: Traditional SSI surveillance
Number of subjects: 204233
Study: 36277481

Group type: EXPERIMENTAL
Intervention: Brepocitinib
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ritlecitinib
Number of subjects: 24
Study: 36277662

Group type: EXPERIMENTAL
Intervention: Invasive treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 0
Study: 36277757

Group type: EXPERIMENTAL
Intervention: Dual pathway inhibition (DPI) by combining acetylsalicylic acid (ASA) with low-dose rivaroxaban for 12 weeks.
Number of subjects: 159

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) monotherapy for a 4-weeks run-in period.
Number of subjects: 159
Study: 36277775

Group type: EXPERIMENTAL
Intervention: ECG risk score (eRiS)
Number of subjects: 5864

Group type: EXPERIMENTAL
Intervention: ECG features in conjunction with CAC
Number of subjects: 5864
Study: 36277907

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Number of subjects: 433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg (open-label period)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Placebo (open-label period)
Number of subjects: 433
Study: 36278119

Group type: EXPERIMENTAL
Intervention: Telerehabilitation programme via video conference with a specialist Multidisciplinary Team (MDT) for comprehensive remote assessments and virtual individualised interventions.
Number of subjects: 97
Study: 36278141

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loving-kindness Meditation (LKM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 36278190

Group type: EXPERIMENTAL
Intervention: Meropenem therapy
Number of subjects: 0
Study: 36278416

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (SBP target 110-<130 mm Hg)
Number of subjects: 5369

Group type: EXPERIMENTAL
Intervention: Standard treatment group (SBP target 130-<150 mm Hg)
Number of subjects: 5369

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 5369

Group type: EXPERIMENTAL
Intervention: Standard treatment group
Number of subjects: 5369
Study: 36278454

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0
Study: 36278845

Group type: EXPERIMENTAL
Intervention: Intentional endometrial injury
Number of subjects: 3703

Group type: COMPARATOR
Intervention: Endometrial injury in early follicular phase (EFP)
Number of subjects: 3703

Group type: COMPARATOR
Intervention: Endometrial injury in late follicular phase (LFP)
Number of subjects: 3703
Study: 36279023

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-positive HER2-negative breast cancer
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-negative breast cancer
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-positive HER2-negative breast cancer with aromatase inhibitors
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-positive HER2-negative breast cancer with tamoxifen
Number of subjects: 1123
Study: 36279162

Group type: EXPERIMENTAL
Intervention: Web-based intervention modules for foster caregivers
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: General parenting information (e.g., parental self-care, emotion regulation management)
Number of subjects: 181
Study: 36279178

Group type: EXPERIMENTAL
Intervention: TLR4-stimulated whole blood
Number of subjects: 135
Study: 36279414

Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 0
Study: 36279618

Group type: EXPERIMENTAL
Intervention: Palbociclib (75, 100, and 125 mg PO daily on days 1 to 21 of a 28-day cycle) in combination with avelumab (10 mg/kg IV every 2 weeks) and cetuximab (400 mg/m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg) in combination with avelumab and cetuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palbociclib, avelumab, and cetuximab combination
Number of subjects: 0
Study: 36279715

Group type: EXPERIMENTAL
Intervention: Tetramer-mediated stimulation of CD8+ T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetramer-sorted CD8+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASR gene signature from tetramer-stimulated pp65-specific CD8+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASR gene signature
Number of subjects: 0
Study: 36279879

Group type: EXPERIMENTAL
Intervention: Hyper-CVAD chemotherapy followed by blinatumomab consolidation (up to 28 μg/day for 28 days, given every 42 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hyper-CVAD chemotherapy followed by blinatumomab consolidation
Number of subjects: 38
Study: 36279923

Group type: EXPERIMENTAL
Intervention: Endoscopic remission
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Histologic remission
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Barrier healing on endomicroscopy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Endoscopically active disease
Number of subjects: 181

Group type: COMPARATOR
Intervention: Histologic activity
Number of subjects: 181
Study: 36280451

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 36280461

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided central venous catheterisation
Number of subjects: 8586
Study: 36280527

Group type: EXPERIMENTAL
Intervention: Elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 438
Study: 36280578

Group type: EXPERIMENTAL
Intervention: Shockwave Therapy and Platelet-rich Plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-controlled
Number of subjects: 0
Study: 36280861

Group type: EXPERIMENTAL
Intervention: Statin plus evolocumab (dual therapy)
Number of subjects: 7556

Group type: EXPERIMENTAL
Intervention: Statin plus ezetimibe (triple therapy)
Number of subjects: 7556

Group type: COMPARATOR
Intervention: PCSK9 inhibitor therapy
Number of subjects: 7556

Group type: COMPARATOR
Intervention: Statin
Number of subjects: 7556

Group type: COMPARATOR
Intervention: Statin plus ezetimibe
Number of subjects: 7556
Study: 36280870

Group type: EXPERIMENTAL
Intervention: SHR-1701 at 30 mg/kg every 3 weeks
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: SHR-1701
Number of subjects: 171
Study: 36281165

Group type: EXPERIMENTAL
Intervention: Sevoflurane at an end-tidal concentration of 1.76 ± 0.15%
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Predicted EC50 of sevoflurane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: End-tidal sevoflurane concentration for successful botulinum toxin injection
Number of subjects: 21
Study: 36281192

Group type: EXPERIMENTAL
Intervention: Continuous glycemia monitoring using Dexcom G5 device before and after surgery (14 days prior and 14 days post-surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard total knee arthroplasty or total hip arthroplasty procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of glycemia levels in patients with normal glycemia metabolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of perioperative glycemic levels
Number of subjects: 0
Study: 36281310

Group type: EXPERIMENTAL
Intervention: Early bupivacaine/tramadol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Late bupivacaine/tramadol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early bupivacaine/dexmedetomidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Late bupivacaine/dexmedetomidine
Number of subjects: 100
Study: 36281983

Group type: EXPERIMENTAL
Intervention: Obstructive CAD
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 959
Study: 36282128

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36282526

Group type: EXPERIMENTAL
Intervention: altASDAS
Number of subjects: 958
Study: 36282533

Group type: EXPERIMENTAL
Intervention: Discussion of HPV vaccine during PCP visit
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Routine vaccination at age 9-10
Number of subjects: 86
Study: 36282618

Group type: EXPERIMENTAL
Intervention: Breastfeeding only support
Number of subjects: 98816

Group type: EXPERIMENTAL
Intervention: Breastfeeding plus support
Number of subjects: 98816
Study: 36282798

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer-related health burden
Number of subjects: 0
Study: 36282800

Group type: EXPERIMENTAL
Intervention: Hemoadsorption
Number of subjects: 1434
Study: 36282833

Group type: EXPERIMENTAL
Intervention: spesolimab
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study: 36283748

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dim light therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Virtual delivery of personalised interventions
Number of subjects: 60
Study: 36283759

Group type: EXPERIMENTAL
Intervention: Toxic occupational exposures (asbestos, organic solvents)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Occupational toxic substance exposure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PLA2R1 epitope spreading
Number of subjects: 100
Study: 36283927

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional Wound Care (CWC)
Number of subjects: 109
Study: 36284205

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 6 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention (Control group: patients without OSA)
Number of subjects: 24
Study: 36284220

Group type: COMPARATOR
Intervention: pegcetacoplan (monthly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: pegcetacoplan (every other month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: pegcetacoplan
Number of subjects: 0
Study: 36284281

Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 36284360

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 60

Group type: COMPARATOR
Intervention: No Steroids (Control)
Number of subjects: 60
Study: 36285530

Group type: EXPERIMENTAL
Intervention: Conjugate vaccines, with some patients on preventive antibiotics (n = 6) and/or immunoglobulins replacement therapy (n = 10)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Not applicable (no specific control group mentioned)
Number of subjects: 118
Study: 36285536

Group type: EXPERIMENTAL
Intervention: Lufotrelvir (50, 150, 500, or 700 mg continuous 24-hour infusion)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lufotrelvir (50-700 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lufotrelvir (270 to 350 mg daily continuous infusion)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 36286004

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride solution applied every 4 weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: 5% potassium nitrate solution applied every 4 weeks
Number of subjects: 148
Study: 36286755

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg 24 hours before CT, 40 mg before CT, and 40 mg after CT (16 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg before CT and 40 mg after CT (33 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No statin therapy (52 patients)
Number of subjects: 100
Study: 36286862

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 510
Study: 36286865

Group type: EXPERIMENTAL
Intervention: Specific drug therapy
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Right heart failure
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 6MWD (6-minute walk distance)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Borg dyspnea index
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Hemodynamic parameters
Number of subjects: 404
Study: 36286918

Group type: EXPERIMENTAL
Intervention: Combinations of 2 oCDs (Atrial Hypertension and Chronic Heart Failure)
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Combinations of 3 oCDs (Atrial Hypertension, Coronary Heart Disease, and Chronic Heart Failure)
Number of subjects: 5808

Group type: EXPERIMENTAL
Intervention: Combinations of 4 oCDs (Atrial Hypertension, Coronary Heart Disease, Chronic Heart Failure, and Diabetes Mellitus)
Number of subjects: 5808
Study: 36287047

Group type: EXPERIMENTAL
Intervention: Positive anti-HLA antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative anti-HLA antibodies
Number of subjects: 0
Study: 36287231

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus R-CHOP (atezo-R-CHOP)
Number of subjects: 42
Study: 36287248

Group type: EXPERIMENTAL
Intervention: Nivolumab combined with ibrutinib
Number of subjects: 24
Study: 36287523

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention group
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention
Number of subjects: 154
Study: 36287602

Group type: EXPERIMENTAL
Intervention: Concentrated, interdisciplinary group pulmonary rehabilitation program
Number of subjects: 50
Study: 36287929

Group type: EXPERIMENTAL
Intervention: High indoxyl sulfate (IS) levels (cutoff 0.365 mg/dL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High myostatin levels (cutoff 4.5 ng/mL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Independently associated factors
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Correlation with glomerular filtration rate (GFR)
Number of subjects: 150
Study: 36288197

Group type: EXPERIMENTAL
Intervention: Score-D (scored based on Kinect visualization)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Score-T (scored by therapist during completion)
Number of subjects: 20
Study: 36288238

Group type: EXPERIMENTAL
Intervention: Cetuximab + Palbociclib
Number of subjects: 10
Study: 36288281

Group type: EXPERIMENTAL
Intervention: CRISPR-engineered CAR19 T cells
Number of subjects: 6

Group type: COMPARATOR
Intervention: Lymphodepletion regimen (fludarabine, cyclophosphamide, and alemtuzumab)
Number of subjects: 6
Study: 36288512

Group type: EXPERIMENTAL
Intervention: GSK2256098
Number of subjects: 36
Study: 36288547

Group type: EXPERIMENTAL
Intervention: Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Teliso-V plus erlotinib
Number of subjects: 42
Study: 36288619

Group type: EXPERIMENTAL
Intervention: LAMP2-positive patients
Number of subjects: 4

Group type: COMPARATOR
Intervention: Choroideremia patient
Number of subjects: 4
Study: 36288714

Group type: EXPERIMENTAL
Intervention: v-ATPase inhibitors (e.g., etidronate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of etidronate
Number of subjects: 0
Study: 36288758

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SAbR) with a median prescribed dose of 45 Gy (range, 35-55) in 5 daily fractions to tumor and 40 Gy (35-45) to nodes.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SAbR)
Number of subjects: 50
Study: 36289001

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Non-General Anesthesia (non-GA)
Number of subjects: 725
Study: 36289094

Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg/day plus Pembrolizumab 200 mg every 3 weeks
Number of subjects: 6
Study: 36289459

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: High-score tercile of metabolites
Number of subjects: 190
Study: 36291172

Group type: EXPERIMENTAL
Intervention: Nigericin-stimulated whole blood samples from healthy donors
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nigericin-stimulated whole blood samples from septic shock patients
Number of subjects: 4
Study: 36291397

Group type: EXPERIMENTAL
Intervention: Leisure time sport
Number of subjects: 505